The Globe and Mail reports in its Thursday, July 20, edition that TD Securities analyst David Kwan has an unchanged "buy" recommendation on Well Health Technologies. The Globe's David Leeder writes in the Eye On Equities column that Mr. Kwan gave his share target a boost to $8.50 from $7.50. Analysts on average target the shares at $8.30. The Globe says Mr. Kwan is feeling pretty good about Well Health after a tour of two of its Vancouver clinics. Mr. Kwan says in a note: "Well Health Technologies remains our top pick. We expect its superior execution to-date to continue, highlighted by its strong organic and M&A-driven growth and healthy margins and FCF that we believe should allow it to take advantage of a very attractive M&A environment." The Globe reported on May 1 that Raymond James analyst Michael Freeman rated Well Health "outperform" in new coverage. It was then worth $5.56. The Globe reported on June 28 that Eight Capital analysts Adhir Kadve and Christian Sgro rated Well Health "buy." In the item, the analysts said, "We see the potential for a product roadmap that ultimately provides a robust AI-assistant to doctors, enabled by Well Health's widely installed EMR and network." It was then worth $4.84.